Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting

Abstract EN

Objective.

Long-term aromatase inhibitor (AI) therapy is expected to improve the health outcomes with high health resource consumption in early breast cancer.

The aim of the study was to assess the cost-effectiveness of letrozole for postmenopausal women with estrogen receptor positive early breast cancer in a health resource-limited setting.

Methods.

A Markov model was developed to project the lifetime outcomes based on the clinical course of early breast cancer.

The clinical and utility data were derived from reported results.

Costs were estimated from the perspective of Chinese health care.

The quality-adjusted life-year (QALY) and incremental cost-effective ratio (ICER) were measured.

Probabilistic sensitivity and one-way analyses were conducted.

Results.

Compared to 5 years of tamoxifen therapy, 5 years of AI treatment with letrozole improved the QALYs (10.44 versus 10.84) and increased the lifetime costs (CNY ¥13,613 versus CNY ¥28,797), resulting in an ICER of CNY ¥38,092 /QALY.

The ICER of 5 years of letrozole versus 2–3 years of tamoxifen and then letrozole was CNY ¥68,233 /QALY.

Sensitivity analyses showed that the age of initiating adjuvant endocrine therapy was the most influential parameter.

Conclusions.

In health resource-limited settings, adjuvant endocrine therapy with letrozole is a cost-effective strategy compared to tamoxifen in women with early breast cancer.